BLISSGVS — Bliss GVS Pharma Share Price
0.000.00%
Last trade - 00:00- IN₹11.70bn
- IN₹11.32bn
- IN₹7.52bn
- 82
- 38
- 79
- 79
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.26 | ||
| Price to Tang. Book | 1.27 | ||
| Price to Free Cashflow | 233.35 | ||
| Price to Sales | 1.55 | ||
| EV to EBITDA | 8.81 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 10.16% | ||
| Return on Equity | 9.86% | ||
| Operating Margin | 13.75% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 8,982.49 | 6,893.09 | 5,772.05 | 7,474.54 | 7,515.88 | n/a | n/a | 15.07% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +574.36 | -14.68 | -37.32 | -31.9 | +51.3 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bliss GVS Pharma Limited is engaged in developing, manufacturing, and marketing pharmaceutical formulations. The Company’s product categories include pharma products and other healthcare products. Its pharma products include pharma products include capsules, creams, gels, ointments, dry powder for injection, effervescent tablets, eye/ear drops, nasal solution, lotions, lozenges, soft gelatine capsules and syrups. The Company’s other healthcare products include balm, nasal inhaler, solution, soap, vaginal wash, roll on, shampoo, powder, spray, and petroleum jelly. Its brands include ANOMEX, ANOMEX DS, CONLAX 5/10, G - ALFENAC 100, GACET 80/125/170/250/500/1G, GMETH - 50/100, GSUNATE - 50/100/200, GVCAM - 7.5/15, GV-SOFT 1/2/3/4 G, LOFNAC - 12.5/25/50/100, MEFINOL, MELANEZ, MENINA - 25/100, TYRIDOL, VIGOTAMIN, COMIT 50, BG - CLIND, VAGID CL, ECOZOLE, GVGYL 500, GYNANFORT, GVGYL N, KLOVINAL, LONART, LONART FORTE, LONART Dispersible, FINMOL, GACET-500, and DOXYCYCLINE.
Directors
- Vipul Thakkar CFO
- Aditi Bhatt CCO
- Gagan Sharma MDR (38)
- Shruti Kamath EDR (30)
- Vibha Kamath EDR (31)
- Shruti Rao EDR (36)
- Vibha Sharma EDR (38)
- Shilpa Bhatia IND
- Subramanian Vaidya IND (71)
- Santosh Parab NID
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 11th, 1984
- Public Since
- July 26th, 2010
- No. of Shareholders
- 43,919
- No. of Employees
- 763
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 104,690,822
- Address
- 102, MUMBAI, 400072
- Web
- https://www.blissgvs.com/
- Phone
- +91 2242160000
- Contact
- Aditi Bhatt
- Auditors
- Kalyaniwalla & Mistry LLP
Upcoming Events for BLISSGVS
Bliss GVS Pharma Ltd Annual Shareholders Meeting
Q1 2025 Bliss GVS Pharma Ltd Earnings Release
Similar to BLISSGVS
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Bliss GVS Pharma share price?
As of Today at 19:04 UTC, shares in Bliss GVS Pharma are trading at IN₹111.80. This share price information is delayed by 15 minutes.
How has the Bliss GVS Pharma share price performed this year?
Shares in Bliss GVS Pharma last closed at IN₹111.80 and the price had moved by +50.27% over the past 365 days. In terms of relative price strength the Bliss GVS Pharma share price has outperformed the S&P BSE 100 Index by +13.89% over the past year.
What are the analyst and broker recommendations for Bliss GVS Pharma?
The overall consensus recommendation for Bliss GVS Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Bliss GVS Pharma dividend yield?
The Bliss GVS Pharma dividend yield is 0.45% based on the trailing twelve month period.
Does Bliss GVS Pharma pay a dividend?
Last year, Bliss GVS Pharma paid a total dividend of IN₹0.50, and it currently has a trailing dividend yield of 0.45%. We do not have any data on when Bliss GVS Pharma is to next pay dividends.
When does Bliss GVS Pharma next pay dividends?
We do not have data on when Bliss GVS Pharma is to next pay dividends. The historic dividend yield on Bliss GVS Pharma shares is currently 0.45%.
How do I buy Bliss GVS Pharma shares?
To buy shares in Bliss GVS Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Bliss GVS Pharma?
As of the previous close price of IN₹111.80, shares in Bliss GVS Pharma had a market capitalisation of IN₹11.70bn.
Where are Bliss GVS Pharma shares listed?
Here are the trading details for Bliss GVS Pharma:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: BLISSGVS
What kind of share is Bliss GVS Pharma?
Based on an overall assessment of its quality, value and momentum Bliss GVS Pharma is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Bliss GVS Pharma share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Bliss GVS Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bliss GVS Pharma. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +5.61%.
As of the last closing price of IN₹111.80, shares in Bliss GVS Pharma were trading +3% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Bliss GVS Pharma PE Ratio?
The Bliss GVS Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹111.80.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Bliss GVS Pharma?
Bliss GVS Pharma's management team is headed by:
- Vipul Thakkar - CFO
- Aditi Bhatt - CCO
- Gagan Sharma - MDR
- Shruti Kamath - EDR
- Vibha Kamath - EDR
- Shruti Rao - EDR
- Vibha Sharma - EDR
- Shilpa Bhatia - IND
- Subramanian Vaidya - IND
- Santosh Parab - NID